BridgeBio Pharma, Inc. Cash and Cash Equivalents, Fair Value Disclosure
BridgeBio Pharma, Inc. (BBIO) had Cash and Cash Equivalents, Fair Value Disclosure of $378.54 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:CashAndCashEquivalentsFairValueDisclosure · last filed 2026-08-10
- 2026-06-30: Cash and Cash Equivalents, Fair Value Disclosure $378.54M.
- 2026-03-31: Cash and Cash Equivalents, Fair Value Disclosure $550.71M.
- 2025-12-31: Cash and Cash Equivalents, Fair Value Disclosure $170.50M.
- 2025-09-30: Cash and Cash Equivalents, Fair Value Disclosure $283.34M.
| Period end | Cash and Cash Equivalents, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $378.54M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $550.71M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $170.50M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $283.34M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $378.11M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $129.92M 10-Q · filed 2025-04-29 |
| 2024-12-31 | $359.79M 10-K · filed 2026-02-24 |
| 2024-09-30 | $219.92M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $323.39M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $444.17M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $269.60M 10-K · filed 2025-02-20 |
| 2023-09-30 | $464.42M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $287.67M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $396.20M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $362.01M 10-K · filed 2024-02-22 |
| 2022-09-30 | $450.59M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $257.29M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $258.40M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $233.10M 10-K · filed 2023-02-23 |
| 2020-06-30 | $443.39M 10-Q · filed 2020-08-11 |
| 2019-12-31 | $307.74M 10-K · filed 2021-02-25 |
| 2019-09-30 | $356.58M 10-Q · filed 2019-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |